Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
|
|
10.
|
|
|
11.
|
|
|
12.
|
|
|
13.
|
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. [electronic resource] by
- Cohn, A L
- Tabernero, J
- Maurel, J
- Nowara, E
- Sastre, J
- Chuah, B Y S
- Kopp, M V
- Sakaeva, D D
- Mitchell, E P
- Dubey, S
- Suzuki, S
- Hei, Y-J
- Galimi, F
- McCaffery, I
- Pan, Y
- Loberg, R
- Cottrell, S
- Choo, S-P
Producer: 20131211
In:
Annals of oncology : official journal of the European Society for Medical Oncology vol. 24
Availability: No items available.
|